[Low molecular weight heparin--1998 status].
Extensive review articles and recent comparative clinical studies demonstrate that low molecular weight heparins are able to cover successfully the prophylactical and therapeutical indications of classical unfractionated heparin. Similar antithrombotic mechanisms but better pharmacokinetic properties are the reason why low molecular weight heparins are about to become the "better heparin". They are the first choice for acute prophylaxis and treatment of venous thromboembolism, for clot prevention in hemodialysis and as good or better than unfractionated heparin for the management of unstable angina pectoris. In the near future studies may prove their antithrombotic efficacy in other parts of the arterial circulation.
Marbet
G A
GA
Hämostaselabor DZL, Kantonsspital Basel.
D000789:Angina, Unstable / Q000188:drug therapy; D000818:Animals; D002986:Clinical Trials as Topic; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D013923:Thromboembolism / Q000188:drug therapy*; D016896:Treatment Outcome
D006495:Heparin, Low-Molecular-Weight; D006493:Heparin
Niedermolekulare Heparine--Stand 1998.